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Abstract
Objective—To examine the effects of apoB100 structure, specifically a mutation in the LDLr 
binding region, on the production of LDL and development of atherosclerosis in vivo.
Methods and Results—Ldlr−/− Apobec1−/− mice lacking the LDLR and apoB editing enzyme 
accumulated LDL in plasma and developed severe atherosclerosis when they had wild-type 
apoB100. In marked contrast, in Ldlr−/− Apobec1−/− mice carrying the Apob100-β mutation, in 
the 2 putative LDLR-binding domains of apoB prevented both LDL accumulation and 
atherosclerosis. Intestinal absorption of lipids and triglyceride secretion from the liver were not 
affected. However, the VLDL particles with apoB100-β were larger in volume by about 70%, and 
carried approximately four times as much apoE per particle. ApoB100-β synthesis rate in the 
primary hepatocytes was normal, but its intracellular degradation was enhanced. Additionally, 
mutant apoB100 VLDL cleared from the circulation more quickly in vivo through apoE-LRP–
mediated mechanism than VLDL with wild-type apoB100. In contrast, uptake of the 2 VLDL by 
macrophages were not different.
Conclusion—While conformational change to apoB100 during conversion of VLDL to LDL 
exposes LDLR binding domains and facilitates LDLR-mediated lipoprotein clearance, it may also 
inhibit LRP-mediated VLDL uptake and contribute to LDL accumulation in familial 
hypercholesterolemia.
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Apolipoprotein (apo) B is an essential component of VLDL, LDL, and chylomicrons. ApoB 
normally exists in 2 forms, apoB100 and apoB48; both are the products of the same gene. 
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ApoB100 comprises 4536 amino acids, synthesized in the liver, and secreted into the 
circulation as a structural component of VLDL. ApoB48 is 48% of full-length apoB, and is 
formed as a result of posttranslational editing of ApoB mRNA by the apoB editing complex 
(apo-BEC), which changes Gln at codon 2153 to a stop codon.1 ApoB48 is synthesized in 
the small intestine and is required for the packaging of lipids into chylomicrons. Whereas 
human liver makes exclusively apoB100, a large proportion of message in the mouse liver is 
edited and consequently mice produce both apoB48 and apoB100 from the liver.2
In addition to maintaining the structural integrity of li-poprotein particles, apoB100 also 
functions as a ligand for the LDLR and is therefore a primary determinant of circulating 
LDL cholesterol levels. The LDLR-binding domain of apoB100 has not been fully defined; 
however, biochemical, immunochemical, and genetic evidence suggests that it is a region of 
net positive change located in the carboxyl-terminal portion of apoB100. Two sequences, 
residues 3147 to 3157 and 3359 to 3367, are enriched in basic amino acid residues and have 
been proposed as putative LDLR-binding domains in both species.3 The sequence at 3359 to 
3367 is highly conserved among mammalian species and is also similar to the LDLR-
binding site of apoE. Also, Boren et al showed that the removal of positive charges from 
residues 3359 to 3367 by site-directed mutagenesis renders the LDL containing the modified 
apoB defective in LDLR binding.3
To define the regions of apoB that bind the LDLR, we previously introduced mutations into 
the mouse Apob gene.4 The apoB100-β protein is the same length as apoB100 but contains 
2 peptide sequences for human β-globin in place of the residues 3147 to 3157 and 3359 to 
3367. The modification also drastically reduced the net positive charges and amphipathic 
helicies of the 2 domains. We expected that the mice producing apoB100-β would model 
defective apolipoprotein B100 in humans by accumulating binding-defective LDL in 
plasma.5 However, we found that the apoB100-β/B100-β mice have slightly, but not 
significantly lower than normal, total plasma cholesterol and HDL cholesterol, and the 
amount of plasma LDL was not different from that in wild-type mice.4 One explanation is 
that these 2 regions are not essential for apoB100 binding to the LDLR in vivo. The 
interpretation, however, is complicated because mice normally have very little apoB100-
containing LDL particles in circulation. In addition, the production of apoB48 from the liver 
and the efficient clearance of apoB48-containing remnants mediated by apoE make the 
metabolism of apoB100 difficult to study in vivo in mice.
The present study examined the effect of apoB100-β-containing LDL by introducing the 
mutation onto a background of Ldlr−/− Apobec1−/− double mutants; a model of human 
familial hypercholesterolemia with severe atherosclerosis. Apobec1−/− mice that lack the 
mRNA editing enzyme produce only apoB100,7 whereas Ldlr−/− mice that lack LDLR 
accumulate LDL cholesterol in plasma.6,7 Surprisingly, when these mice also carry the 
apoB100-β mutation, they are completely protected from hypercholesterolemia and 
atherosclerosis that normally occurs in Ldlr−/− Apobec1−/− mice.
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Please see supplemental methods (available online at http://atvb.ahajournals.org) for details 
on plasma lipid, lipoprotein, tissue weight, triglyceride secretion, lipolysis, uptake of DiI 
and 125I-labeled lipoproteins, LRP inhibition by adenoRAP, gene expression, and apoB 
synthesis, secretion, and degradation.
Animals and Diets
The apoB100-β allele codes for “VHLTPVEKSAVT” and “KEFT-PPVQAAYQ” instead of 
“LSVKAQYKKNSD” and “GTSRLM-RKRGLK” of the wild-type apoB100 allele at 
residues 3143 to 3154 and 3356 to 3366, respectively.4 Ldlr−/− mice (B6;129S7-Ldlrtm1Her/J) 
were obtained from the Jackson Laboratory. Apobec1−/− mice were obtained from Dr Eddy 
Rubin at the Lawrence Berkeley National Laboratory.7 Three strains of mutants were 
crossed to generate mice that are heterozygous for the Apob locus and doubly homozygous 
for the Apobec1 and the Ldlr loci. These mice were then crossbred, and Ldlr−/− Apobec1−/− 
mice with Apob genotypes of 100/100 (wild type), 100/100-β (heterozygous), and100-β/
100-β (homozygous) were generated for experiments. Their genetic backgrounds were 
complex mixes between C57BL/6J, 129/SvEv, and129/Ola. Animals were maintained on 
normal chow (NC; 4.5% fat, 0.022% cholesterol; Prolab Isopro 3000; Agway Inc), or were 
fed a high-fat Western-type diet (HFW; 21% fat, 0.2% cholesterol; TD 88137; Harlan 
Teklad). Mice in all experiments were age-matched within 3 weeks. All procedures for the 
handling of mice were approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill.
Biochemical Analyses and Atherosclerosis Evaluation
Mice were fasted 4 hours before analysis. Liver and fecal lipids were extracted with 
chloroform/methanol.8 Plasma lipids, lipoprotein distribution, and triglyceride secretion rate, 
were determined as described.9 Lipoprotein particle diameters were determined by dynamic 
light scattering analysis using a Microtrac 250.10 Peritoneal macrophages and hepatocytes 
were isolated as described.11,12 The VLDL (d <1.006 g/mL) and LDL (d=1.06 to 1.10 g/mL) 
fraction was isolated from pooled plasma by ultracentrifugation and labeled with 1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI C18; Molecular Probes 
Inc)13 or with 125I (Iodine-125 Radionuclide, Perkin Elmer)14 for clearance assays. 
Fibroblasts were kindly provided by Dr J. Herz at the University of Texas Southwestern 
Medical Center. Cellular lipids were extracted with isopropanol and measured with a 
microscope fluorometer.13 Gene expression in the liver was analyzed by real-time 
polymerase chain reaction (PCR), and quantification of atherosclerosis was carried out as 
described.11
Data Analysis
Values are reported as mean±SEM unless otherwise stated. Data were analyzed by ANOVA 
using JMP software (SAS Inc).
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ApoB100-β Causes Marked Reduction of LDL in Ldlr−/− Apobec1−/− Mice
Ldlr−/− Apobec1−/− mice with wild-type apoB100 had high levels of plasma cholesterol and 
triglycerides on NC, and further increased plasma lipids on a HFW diet (Table). In contrast, 
both plasma cholesterol levels in the Ldlr−/− Apobec1−/− mice that are heterozygous and 
homozygous for the apoB100-β mutation were reduced in an allele dose-dependent manner. 
The protective effect of the apoB100-β mutation compared to controls was retained when 
mice were fed a HFW diet, although plasma cholesterol levels increased about 3-fold in all 
mice. Plasma levels of triglyceride, free cholesterol, and phospholipids in mice with 
apoB100-β were also significantly lower than those with apoB100 mice.
When plasma lipoproteins from male mice on normal chow diet were analyzed by fast 
protein liquid (FPLC), more than 60% of the plasma cholesterol was in the LDL fraction in 
Ldlr−/− Apobec1−/− mice with wild-type apoB100. In contrast, a striking absence of LDL-
cholesterol was noted in the plasma of Ldlr−/− Apobec1−/− mice homozygous for apoB100-β 
(Figure 1A). Mice with one copy of apoB100-β had approximately half the amount of LDL 
as those with wild-type apoB100. All mice had very low levels of VLDL cholesterol, and 
there was no difference in the amount of HDL. The possession of apoB100-β resulted in a 
similar reduction of triglycerides in the LDL fraction (Figure 1B). SDS gel electrophoresis 
of lipoprotein fractions from plasma of mice fed a HFW diet showed that the distribution of 
apoB100-β among various classes of lipoproteins was similar to that of normal apoB100 
with the highest concentration in the LDL range (1.02 g/mL>d >1.04 g/mL, Figure 1C). 
However, total apoB100-β in these mice was much less than wild-type apoB100, because 
samples of 3 times of apoB100-β plasma volume was loaded compared to apoB100 plasma. 
Total plasma apoE was also less in mice with apoB100-β than in mice with apoB100, but the 
ratio of apoE/apoB on the lipoprotein particles in the apoB100-β mice was about 4 times 
higher than in apoB100 mice.
Although there was no difference in adipose tissue weight, the liver weight per body weight 
was slightly but significantly smaller in mice with apoB100-β (P<0.005, Figure 1D). 
Hepatic intracellular cholesterol pools in the 2 groups of mice were not significantly 
different after 2 months on HFW diet. In contrast, the liver triglyceride content of Ldlr−/− 
Apo-bec1−/− males with apoB100-β was significantly lower than in mice with wild-type 
apoB100 (P<0.001, Figure 1E). Fecal cholesterol and triglyceride levels of mice after 2 
months on HFW diet were not significantly different (Figure 1F). These data suggest that the 
apoB100-β mice are also protected from liver steatosis. Under light microscopy, however, 
liver sections from mice on HFW contained similar degrees of fatty droplets and no 
remarkable difference was observed between the Apob genotypes (data not shown).
Ldlr−/− Apobec1−/− Mice With apoB100-β Secrete Larger VLDL
A possible source of the disparity in plasma LDL levels is a difference in hepatic VLDL 
production rates. To estimate the secretion rate of triglyceride-rich lipoprotein (TRL) 
particles from the liver, we injected Triton WR1339 (Tyloxapol) intravenously into mice to 
inhibit lipolysis and uptake of TRLs, and measured plasma triglycerides (Figure 2A). 
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Although the basal triglyceride levels differ in the 2 groups of mice, triglyceride secretion 
rates were nearly identical at 280 to 300 μg/mL/h regardless of whether they have apoB100 
or apoB100-β.
We next analyzed VLDL particle size at 2 hours post-Tyloxapol injection. The size of 
particles in the <1.006 g/mL density fraction was significantly different between the 2 
groups of Ldlr−/− Apobec1−/− mice; the mean±SD diameter of apoB100-β VLDL particles 
were larger (55.0±15 nm) than those with wild-type apoB100 (45.6±14 nm). Based on the 
difference in the diameter, we estimate that the average apoB100-β VLDL has 
approximately 46% more surface area and 76% greater volume than that of the normal 
apoB100 VLDL. Assuming that the triglyceride content of a particle is relative to its 
volume, this implies that the number of VLDL particles secreted from the Ldlr−/− 
Apobec1−/− liver with apoB100-β is approximately 60% that from the liver with wild-type 
apoB100.
To examine the production and degradation of apoB100 proteins, we conducted a pulse-
chase experiment with radio-labeled methionine in the primary hepatocytes isolated from the 
Ldlr−/− Apobec1−/− mice with apoB100 and with apoB100-β (Figure 2B). 
Immunoprecipitable apoB protein in the apoB100-β cells after the 30-minute pulse was not 
significantly different from that in apoB100 cells, suggesting that the initial synthesis rates 
are not different. After 4-hour chase in the medium with excess of cold methionine, 
however, the immunoprecipitable apoB protein both in the medium and associated with cells 
was significantly less in the apoB100-β hepatocytes. Thus, the mutated apoB protein is 
degraded more quickly, leading to the reduced number of VLDL particles secreted from the 
Ldlr−/− Apobec1−/− liver with apoB100-β.
B100-β VLDL Is Efficiently Cleared From the Circulation
The lack of LDL accumulation in the Ldlr−/− Apobec1−/− mice with apoB100-β is not 
proportional to the amount of VLDL particles secreted in these mice compared to that in 
mice with wild-type apoB. To test a hypothesis that apoB100-β VLDLs are cleared more 
efficiently than apoB100 VLDL, we isolated VLDL from Ldlr−/− Apobec1−/− mice with 
either apoB100 or apoB100β, labeled them with 125I, and injected them into Ldlr−/− mice 
via the tail vein. Monitoring plasma clearance of 125I labeled VLDL over a 2-hour period 
showed that 125I VLDL with apoB100-β are cleared faster than VLDL with wild-type 
apoB100 (Figure 3A). To determine the specific tissue loci of the cleared VLDL, we 
repeated the 125I-VLDL turnover, this time measuring radioactivity in various tissues after 
20 minutes. Of 125I-VLDL cleared, the majority was found in the liver. The distribution 
of 125I-VLDL with apoB100β did not differ from that of 125I-VLDL with apoB100 in the 
five organs measured (Figure 3B).
To assess the conversion of VLDL to smaller particles in vivo, plasma samples were isolated 
from mice 2 hours after 125I-VLDL injection, pooled, and separated into VLDL, IDL, and 
LDL fractions using ultracentrifugation. Proportions of counts in the density fractions 
containing each class of lipoproteins were similar between mice received 125I-VLDL with 
apoB100 and those with apoB100-β (Figure 3C). Furthermore, the apoB100-β VLDL 
particles incubated with postheparin plasma released FFA at rates of 12±1 nmol FFA/min 
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compared to apoB100 VLDL at 11±1 nmol FFA/ min (Figure 3D), suggesting that the lack 
of putative LDLR binding domain sequences of apoB does not affect the lipolysis of VLDL 
in Ldlr−/− Apobec1−/− apoB100-β mice.
Taken together, these experiments suggest that the absence of hyperlipidemia in LDLR-
deficient mice having apoB100 without the putative receptor-binding sequences is likely 
because their VLDL particles are quickly cleared from the circulation before they become 
small, cholesterol-enriched LDL particles.
Role of ApoE-LRP–Mediated Clearance
To examine the specific roles of the LRP on apoB100-β particle uptake, we measured uptake 
of DiI labeled VLDL and LDL in mouse fibroblasts deficient in either LDLR (LDLR−/− 
LRP+/+), in LRP (LDLR+/+LRP−/−), or in both LDLR and LRP (LDLR−/− LRP−/−, negative 
control cells). Two hours after DiI-labeled apoB100-LDL was added to the medium, the 
uptake into LDLR+/+LRP−/− cells was significantly higher than in LDLR−/− LRP−/− negative 
control cells (Figure 4A). The uptake of apoB100-LDL by the LDLR−/− LRP+/+ cells was 
also higher than in negative control cells. Uptake of apoB100-β LDL was not increased by 
the expression of either LDLR or LRP. The opposite pattern of uptake was observed in 
studies with VLDL. In 30 minutes, DiI-labeled apoB100-β-VLDL was efficiently taken up 
by cells expressing LDLR, and particularly LRP, whereas no such increase over the uptake 
by negative control cells was found in cells given DiI-labeled-apoB100 VLDL (Figure 4B).
We next blocked hepatic LRP function using Ad-RAP to determine the role of the LRP in 
the clearance of apoB100-β VLDL in vivo. While basal cholesterol and triglyceride levels in 
plasma are significantly lower in Ldlr−/− Apobec1−/− mice with apoB100-β than those with 
normal apoB100, the levels 5 days after Ad-RAP injection were not different between the 2 
groups of mice. FPLC analyses showed a similar accumulation of cholesterol in the VLDL 
fraction after 5 days in both groups (supplemental Figure I). These data imply that apoB100-
β VLDL is removed by receptors inhibited by RAP, such as LRP. We also examined the 
contribution of HSPG binding by incubating LDLR−/− LRP−/− cells at 4°C with DiI-VLDL. 
The amount of VLDL released from the surface by heparinase after 2 hours was not 
significantly different (supplemental Figure II), suggesting that apoB100-β does not affect 
the binding ability of VLDL to proteoglycans.
To gain further insight into the apparent enhancement of lipoprotein clearance in Ldlr−/− 
Apobec−/− mice with apoB100-β, we analyzed the expression of the Apob, Apoe, and Lrp1 
genes in the liver by real-time PCR. Although there was no Apob genotype effect on the 
mRNA levels for Apob and Lrp1, liver expression of Apoe was approximately twice as high 
in mice with apoB100-β as in mice with wild-type apoB100 (supplemental Figure III). 
These data, combined with the higher apoE:apoB protein ratio, suggest that the increased 
production of apoE protein may be contributing to the accelerated clearance of apoB100-β 
containing VLDL-remnants and the resistance to hyperlipidemia in the apoB100-β mice 
even in the absence of LDLR.
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Ldlr−/− Apobec1−/− Mice With ApoB100-β Are Protected From Development of 
Atherosclerosis
High levels of LDL are a well-documented risk factor for atherosclerosis. Ldlr−/− Apobec−/− 
female mice with apoB100 had a significant size of lesions (34±6×103μm2), even when they 
were on NC diet and were as young as 4 to 5 months old (Figure 5A). In marked contrast, 
the apoB100-β mutation demonstrated a significant atheroprotective effect. Although 3 of 5 
Ldlr−/− Apobec−/− mice heterozygous for apoB100-β had visible plaques (16±7×103μm2), 
there were absolutely no plaques seen in mice homozygous for the apoB100-β mutation. 
The overall effect of the Apob genotype on plaque development was P<0.002 by ANOVA. 
Feeding a HFW diet for 2 months accelerated the plaque development in the Ldlr−/− 
Apobec−/− mice with apoB100 (mean lesions size 54±8 x103μm2; n=5). In contrast, there 
were virtually no lesions present in apoB100-β mice but only very small foam cell 
aggregations (1.7±0.8×103μm2, P<0.002).
To examine whether direct VLDL scavenging by macrophages rather than LDL 
accumulation is responsible for the dramatic differences in atherosclerosis, we isolated 
peritoneal macrophages from Ldlr−/− mice and incubated with equal amounts of DiI-labeled 
VLDL in the medium. Uptake of the DiI-VLDL with apoB100 by the macrophages was a 
little more enhanced compared to that with apoB100-β, but the differences were not 
statistically significant (Figure 5B). A similar result was obtained in the macrophages 
isolated from wild-type mice (data not shown), indicating that the scavenging by 
macrophages of the VLDL is not affected by the apoB100-β mutation.
Taken together our data demonstrate that, even in the absence of LDLR, a mutation in the 
putative receptor binding domains of apoB prevents LDL accumulation, and dramatically 
reduces atherosclerosis.
Discussion
LDL is generated in the circulation from VLDL produced by the liver after lipolysis and 
exchange of surface apolipoproteins. During this conversion, conformational changes occur 
in its structural protein, apoB100, allowing for the exposure of domain(s) that interact with 
LDLR.15–17 Exposure of the receptor-binding domain and subsequent binding of apoB100 
to the LDLR is the major pathway for the clearance of LDL cholesterol by the liver, as 
illustrated by the marked accumulation of LDL in plasma of patients and in animals lacking 
LDLR.18 –21 Particles that lack full-length apoB, such as apoB48-containing chylomicron 
remnants, can acquire apoE which mediates efficient clearance of these particles by the 
LDLR, LRP, and other receptors which may act in concert with proteoglycans.22
To investigate the mechanisms for the uptake of apoB48-and apoB100-containing 
lipoproteins by the LDLR and by the LRP, Veniant et al previously characterized plasma 
lipoproteins in the Ldlr−/− mice homozygous for an “apoB48-only” allele or homozygous for 
an “apoB100-only” allele.24 The authors concluded that the LDLR plays a significant role in 
the clearance of both apoB100- and apoB48-containing lipoproteins, and that the LRP is 
important for apoB48-containing lipoproteins but has little if any capacity to remove 
apoB100-containing lipoproteins from the plasma. The “apoB100-only” Ldlr−/− mice are 
Johnson et al. Page 7













phenotypically identical to the Ldlr−/− Apobec1−/− mice with wild-type apoB100 we used in 
the current study. Interestingly, the plasma lipids and lipoprotein distribution in Ldlr−/− 
Apobec1−/− mice with mutant apoB100-β are very similar to “apoB48-only” Ldlr−/− mice, 
despite that apoB100-β retains the full length of the apoB protein. Both strains of mice have 
no substantial accumulation of LDL particles, suggesting that apoB100-β remnants, like 
apoB48-only remnants, are cleared via LRP in the absence of LDLR and that the length of 
apoB protein does not influence this process. However, whereas Veniant et al showed that 
LRP inhibition with RAP of “apoB48-only” Ldlr−/− mice leads to higher VLDL levels than 
in “apo-B100-only” Ldlr−/− mice,23 VLDL accumulation in the Ldlr−/− Apobec1−/− mice 
with apoB100 and those with apoB100-β were similar after LRP inhibition, suggesting that 
additional mechanisms may present in the protective effects noted in the apoB100-β–
producing mice.
The Ldlr−/− Apobec1−/− mice with apoB100-β do not accumulate substantial LDL particles 
in plasma even when fed a HFW diet. This lack of LDL accumulation occurs despite the 
inability of apoB100-β-containing LDL to be cleared in vitro. Importantly, the livers of 
Ldlr−/− Apobec1−/− mice with apoB100-β appear to produce a smaller number of larger 
VLDL particles than the livers of the Ldlr−/− Apobec1−/− mice with apoB100, despite equal 
expression of the Apob gene and protein synthesis. However, the reduction of LDL 
cholesterol in the Ldlr−/− Apobec1−/− mice with apoB100-β is more than the reduction of 
apoB secreted. This is in contrast to the report by Crooke et al that Ldlr−/− mice treated with 
an apoB antisense oligonucleotides had a reduction of apoB mRNA by 74% but still had 
48% levels of LDL-cholesterol compared to the pretreatment levels.24 It has long been 
recognized that the larger VLDL particles are removed faster and less likely converted to 
LDL than smaller VLDL, and a larger surface area of apoB100-β VLDL may allow more 
apoE to associate with the particle and facilitate LRP mediated uptake.25,26 The Ldlr−/− 
Apobec1−/− mice with apoB100-β have plasma lipoproteins containing 4-fold higher apoE 
protein per particle, and 2-fold higher Apoe gene expression in the liver than mice with 
apoB100. All together, these changes favor the enhanced clearance of apoB100-β containing 
particles via the LRP.
We also observed an enhanced degradation of apoB100-β in primary hepatocytes from the 
Ldlr−/− Apobec1−/− mice with apoB-100β in culture. Whether the accelerated degradation of 
apoB100-β results from its abnormal protein folding or is the consequence of enhanced 
turnover has yet to be determined. Although a limited apoB protein available for lipoprotein 
assembly could account for the larger size of VLDL, a question remains as to whether 
apoB100-β fails to form subsets of VLDL particles that are predestined to form LDL 
particles. Studies have demonstrated that a substantial amount of newly synthesized apoB 
protein is degraded rather than secreted, and that its interaction with LDLR channels apoB 
toward presecretory degradation.27–30 Reuptake of newly synthesized lipoproteins by LDLR 
can also attenuate VLDL secretion, and both apoE and apoB are important for this 
process.31,32 Loss of these regulations results in an increased secretion of apoB proteins and 
smaller, underlipidated VLDL particles in humans and mice that lack functional LDLR.33
The metabolism of lipoproteins with apoB100-β mutation is consistent with other 
observations. For example, truncations of apoB on the C-terminal side of amino acid 3500 
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result in more efficient clearance of VLDL.34 Individuals heterozygous for a R3480P 
mutation in apoB exhibit hypo-betalipoproteinemia because of a reduced conversion of 
VLDL to LDL, despite that this mutation caused reduced binding of LDL to the LDLR.35 
Similarly, milder than expected hyperlipidemia in individuals with familial defective 
apolipoprotein B-100 attributable to mutations at R3500 has been attributed to an enhanced 
removal of apoE-containing VLDL and decreased production of LDL.36,37 The apoB100-β 
mutation may also affect a process of structural/ conformational change of apoB100 that is 
important for the in vivo generation of LDL particles as well as for LDLR binding, although 
interpretation is complex because amino acid changes disrupting amphipathic helices 
represented by sites A and B likely cause additional conformational changes of apoB on 
LDL and VLDL. Systematic replacements of the basic LDLR binding sequences with acidic 
or neutral residues would provide a potentially less disruptive and comprehensive approach. 
Chatterton et al hypothesized that the apoB100 “bow”, where a segment of apoB100 crosses 
over itself between amino acid residues 3000 and 3500, inhibits interaction of apoB100 
protein with LDLR, hence inhibiting clearance.38 Because the apoB100-β mutation at amino 
acids 3147 to 3157 and 3359 to 3367 are within the proposed bow crossing structure, a 
mutation in these sequences may physically block or otherwise disrupt “bow” structure 
formation.
There is little doubt that the exposure of the positively charged domains of apoB100 to the 
lipoprotein surface after conformational changes is required for the effective clearance of 
LDL through LDLR. Considering the overall consequences of the mutations in the second 
half of the apoB100, however, it is tempting to speculate that the exposure of the positively 
charged domains of apoB100 may also inhibit the accumulation of apoE on the particles 
required for their apoE-mediated uptake via LDLR or LRP. This is consistent with the 
hypothesis raised by Veniant et al that the presence of the carboxyl half of apoB100 (amino 
acids 2153 to 4536) on the surface of the lipoprotein prevents the lipoprotein particle from 
binding a “sufficient dose of supplemental apoE” that is necessary for the lipoprotein 
particle to escape circulation via uptake by the LRP.23 Lack of the putative LDLR binding 
domains in apoB100-β may also prevent the secretion of newly packaged but underlipidated 
particles by enhancing the degradation of apoB through enhanced interactions between apoE 
and LDLR/LRP.
In conclusion, we have demonstrated that the mutation in the LDLR binding domains of 
apoB100 dramatically protects mice from both hypercholesterolemia and atherosclerosis that 
develop in the absence of LDLR. Our observations raise an intriguing possibility that an 
interference of the exposure of the putative LDLR-binding domains to the lipoprotein 
surface may indeed enhance remnant clearance through apoE-mediated mechanisms. This 
may be applicable as a potential therapeutic approach for preventing LDL accumulation in 
patients with familial hypercholesterolemia.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Plasma lipoprotein distribution by FPLC (A) cholesterol, (B) triglycerides. C, SDS-PAGE of 
apoB100, apoB-100β, and apoE in VLDL to LDL (1.006 to 1.06 g/mL) density fractions. 
Samples equivalent to 5 μL of apoB100 plasma and 15 μL of apoB100-β plasma were 
loaded. M, weight markers. D, Tissue weight normalized to body weight, (E) liver lipid 
contents, and (F) fecal lipids. Number of animals is in each bar. Error represents SEM. 
*P<0.005, **P<0.001.
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A, Hepatic triglyceride secretion rates. Female mice (5- to 8-month-old fed a HFW, n=11) 
were injected via tail-vein with Triton WR-1339, and plasma triglyceride levels were 
measured postinjection. B, 35S Pulse-chase analysis in primary he-patocytes. ApoB100 
bands in the Gel were quantified using Image J software. Error represents SEM. *P<0.005, 
**P<0.001.
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A, Clearance of 125I labeled apoB100 or B100-β VLDL in Ldlr−/− Apobec1−/− mice. n>3 for 
each group. B, Organ uptake expressed as the percentage of total 125I-VLDL in all organs 
measured. n=3 for each group. C, Conversion of injected 125I-VLDL after 2 hours, 
expressed as a percentage of injected VLDL. D, FFA release in heparin treated plasma from 
Ldlr−/− Apobec1−/− mice with apoB100 or apoB100-β measured over 1 hour.
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Uptake by fibroblasts of DiI-labeled lipoproteins with apoB100 or apoB100-β. A, Cells were 
incubated with DiI-labeled LDL 37°C for 2 hours or (B) VLDL for 30 minutes. Error 
represents SEM. *P<0.05, **P<0.005 against uptake in LDLR-LRP cells. #, P<0.05 between 
genotypes within the same cell system.
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A, Atherosclerotic plaque sizes at the aortic roots of 4-month-old female Ldlr−/− Apobec1−/− 
mice. Number of animals is in parentheses. B, Macrophage VLDL uptake. Ldlr−/− 
Apobec1−/− macrophages were incubated with DiI-labeled VLDL with apoB100 or with 
apoB100-β. Cellular florescence is expressed as Arbitrary Units (AU) per cell gram of cell 
protein.
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